分類彙整:生醫新知

Why coronavirus antibody testing in one Colorado town could provide a way forward

Testing in the ski town Telluride could allow for fewer restrictions nationwide. 繼續閱讀

發表於 COVID-19最新動態, 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

「我們的任務是在這個非我所願的複雜混沌的時刻,展示自己最好的品格和行為。願我們與智慧和風度同行。」– Lawrence Bacow, President of Harvard University

Telluride, CO (March 19, 2020) –United Biomedical, Inc. (UBI) and its subsidiary c19 are taking on the COVID-19 pandemic by partnering with San Miguel County, Colorado, to be the first in the United States to test an entire county with their COVID-19 antibody test for the SARS-CoV-2 virus. The testing is being offered free of charge by UBI and c19 and will be administered by the Public Health Department of San Miguel County, with the goal of detecting and containing community spread, and providing a more accurate assessment of disease prevalence. 繼續閱讀

發表於 COVID-19最新動態, 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

Frequently asked questions about UBI SARS-CoV2 ELISA

Who is the UBI Group? 

UBI Group was founded in 1985 and currently has over 5 operating entities and 950 employees globally. We have facilities in China, Taiwan, Ireland and the US. For the past three decades, we have developed, manufactured and sold HIV, HCV, HTLV and FMDV blood diagnostic kits worldwide through various distribution partners including Organon Teknika and BioMerieux. We have also developed, manufactured and sold over 4.5 billion vaccines and ~500 million doses annually through partners. Dr. Chang Yi Wang, our Chief Scientific Officer, is inventor and author of over 100 patents and peer-reviewed publications. She has, together with the UBI team, pioneered the employment of antigenic peptides in the development of  4 blood screening test kits for detection of antibodies to HIV, HCV, HTLV I/II and FMDV for identification and differentiation of viral infections and 2 licensed synthetic peptide based vaccines (FMDV and LHRH) which are globally distributed. She has been awarded Inventor of the Year Award (NYPLA), Pioneer in Technology Award (BMSF), and recipient of funding from Gates Foundation, MOEA and multiple NIH grants over $20M, including for SARS antibody screening diagnostic work. She is currently collaborating with Dr. Anthony Fauci/NIAID and colleagues on HIV functional cure program, and discussed extensively with Dr. Redfield in this area, both leaders in the coronavirus response today.  繼續閱讀

發表於 COVID-19最新動態, 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

為什麼一個科羅拉多州的小縣可以讓所有居民做新冠肺炎篩檢?

科羅拉多州的聖米格爾縣是一個很小的縣,居民人數只有8000人,縣裡沒有醫院,公共衛生部門只有3位職員。在縣內有一個小鎮叫做特柳賴德鎮,這個小鎮雖然小,卻是一個旅遊勝地,經常有來來往往的旅客,因此使得居民暴露在新冠肺炎傳染的風險中。

聯合生物醫學公司 (United Biomedical) 的執行長及共同創辦人Mei Mei Hu和Lou Reese夫婦居住在特柳賴德鎮,當他們夫婦得知小鎮醫療資源不足後,就答應捐贈新冠肺炎篩檢的套件,讓聖米格爾縣的所有居民都能接受篩檢。 繼續閱讀

發表於 COVID-19最新動態, 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

Why a Tiny Colorado County Can Offer COVID-19 Tests to Every Resident

San Miguel County in Colorado has, in ordinary times, fewer than three full-time employees in its public-health department. It has no hospital. Its total population is only 8,000. And yet last week, the county became the first in the United States to announce that it would be offering all its residents a new kind of test for COVID-19. 繼續閱讀

發表於 COVID-19最新動態, 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥抗體新藥UB-221獲中國NMPA核准進行臨床I期試驗

聯合生物製藥(股)公司(聯生藥)今日宣佈,中國國家藥品監督管理局(National Medical Products Administration,NMPA)已核准其開發中抗體新藥UB-221之I 期臨床試驗的申請。此試驗將在健康受試者中評估單劑量UB-221的安全性、耐受性、藥物動力學與藥理學。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers

Taipei, Taiwan – Mar. 20 2020 –United BioPharma (UBP) announced approval of an Investigational New Drug (IND) application from China National Medical Products Administration (NMPA) to conduct a phase 1 clinical trial with the company’s anti-IgE UB-221 monoclonal antibody (mAb). 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯亞生技四路並進 攻堅新冠肺炎病毒帶來的災難

聯亞生技集團於3月19日受新竹科學園區管理局之邀請參加記者會,於記者會由聯亞藥業研發營運長彭文君博士代表集團發表有關COVID-19檢測試劑、疫苗及治療藥物之近期開發進度。

新冠肺炎(COVID-19)疫情自2019年底爆發至今,情勢愈益嚴峻,疫情仍正加速在全球升溫,為了這場與新冠肺炎病毒的超級戰役,UBI集團董事長暨科學長王長怡博士與團隊投入對2019-nCoV病毒的抗體診斷試劑及對抗COVID-19的疫苗與治療藥物之設計,運用其在功能性抗原學逾30年的研究與商業化經驗,以及在重組蛋白藥物領域的20年產業經驗,展開一系列的產品開發計畫,包括: 繼續閱讀

發表於 COVID-19最新動態, 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

檢測試劑來了!美FDA授權開賣

檢測試劑來了! 美FDA授權開賣 繼續閱讀

發表於 COVID-19最新動態, 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients

Taipei, Taiwan – March 17, 2020 – United BioPharma (UBP) announced today that they have received Investigational New Drug (IND) approval from China National Medical Products Administration (NMPA) to conduct a Phase 2 clinical trial to evaluate UB-421’s efficacy on reduction of latent HIV reservoirs in Antiretroviral Therapy (ART)-stabilized HIV patients. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請

聯合生物製藥(股)公司(聯生藥)今日宣佈,中國國家藥品監督管理局(National Medical Products Administration,NMPA)核准其治療HIV-1感染抗體新藥UB-421之II 期功能性治癒概念驗證臨床試驗的申請。此試驗將在穩定接受「抗逆轉錄病毒治療 (Anti-retroviral Therapy,ART)」的 HIV-1感染患者中,研究UB-421與ART 聯合使用對於降低病患體內 HIV 病毒儲存庫 (HIV reservoir)的效果, 類似之方案目前也正在台灣進行臨床試驗中。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

预防 2019 年新型冠状病毒 (2019-nCoV) 传播给家庭和社区中其他人的暂行指南

本暂行指南基于目前已知的有关 2019 年新型冠状病毒 (2019-nCoV) 和其他病毒的呼吸道感染传播情况。美国疾病控制与预防中心 (CDC) 将根据需要并在获得更多信息时,更新此暂行指南。 繼續閱讀

發表於 COVID-19最新動態, 生醫新知, 社會經濟 | 發表迴響

PharmaBoardroom’s Women to Watch 2020

To celebrate International Women’s Day 2020, PharmaBoardroom brings you insights from some of the most inspirational female industry leaders we have had the privilege of talking to over the past 12 months. 繼續閱讀

發表於 Chang Yi Wang, 人物側寫, 公司新聞, 王長怡, 生醫新知, 社會經濟 | 發表迴響

聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」

聯合生物製藥(股)公司(聯生藥)今日宣布,其愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」。

國家新創獎是國內生醫與健康領域研發成果的最高指標獎項,對於曾經獲頒國家新創獎後又持續精進創新且研發進程具體者,可申請續獎。UB-421於2015年首次獲頒國家新創獎,因後續研發成果具體而優異,從而榮獲今年度新創精進獎。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於 多重抗藥性HIV感染病患之臨床試驗協議

聯合生物製藥(股)公司(聯生藥)今日宣布,已和美國國家衛生研究院/過敏與傳染症研究所 (NIH/NIAID) 完成臨床試驗協議簽署,NIAID將贊助UB-421應用於治療多重藥抗藥性(Multiple Drug Resistance,MDR)HIV感染之臨床試驗。根據此協議,NIAID將負責提交Investigational New Drug Application (IND)並執行名為「A Single arm Open Label Phase 2 trial of anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with Multi-Drug Resistant HIV-1 Infection (UB-421結合優化背景抗逆轉錄病毒療法應用於多重抗藥HIV-1感染病患的單臂開放式2期試驗)」的臨床研究,聯生藥則負責提供研究藥物UB-421,以及執行藥物動力學和免疫原性分析試驗。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響